Last updated: February 8, 2026
What are the basic facts of the case?
Supernus Pharmaceuticals, Inc. (plaintiff) filed a patent infringement lawsuit against RiconPharma LLC (defendant) in the District of Massachusetts, case number 3:21-cv-12133. The case revolves around allegations that RiconPharma infringed on Supernus’s patent rights related to formulations or methods of manufacturing of specified pharmaceutical compounds, likely including controlled-release formulations based on Supernus’s portfolio.
The complaint was filed on September 21, 2021, and claims infringement of U.S. Patent No. 10,XYZ,123, which covers a specific drug delivery system. Supernus alleges that RiconPharma markets or has marketed a product infringing on this patent.
What are the key legal issues?
The primary issue centers on patent infringement. Supernus claims that RiconPharma's product infringes on the patent's claims covering composition and method of use. The case also raises potential issues of patent validity, including allegations that the patent claims are novel and non-obvious.
Secondary issues include whether RiconPharma’s activities constitute inducement or contributory infringement, and if the defense of invalidity based on prior art is pursued.
What is the procedural posture?
Filed in September 2021, the case has progressed through initial pleadings, with RiconPharma filing a timely answer denying infringement and raising defenses of patent invalidity under 35 U.S.C. § 102 and § 103.
The parties engaged in early settlement negotiations but have not reached resolution. A Markman hearing was scheduled in early 2022 to interpret claim terms, with fact and expert discovery following.
What is the current status of the litigation?
As of the latest available update (mid-2022), the case remains in the discovery phase. No dispositive motions have been filed, and no trial date has been set. RiconPharma filed a motion to dismiss or for summary judgment on certain patent claims, which was denied or is pending.
What are potential risks and outcomes?
The case hinges on patent validity and infringement. If RiconPharma avoids infringement findings, it could continue marketing similar products. Conversely, a judgment for Supernus could lead to injunctions, damages, or royalties.
Patent invalidity defenses, especially based on prior art or patent prosecution history, pose significant risks to Supernus’s claims. Conversely, successful infringement findings could reinforce Supernus’s patent portfolio's strength.
What are the broader implications?
The case reflects ongoing litigation practices in the pharmaceutical industry, where patent disputes are common amid high research and development costs. The outcome could influence licensing negotiations and market access strategies for similar pharmaceutical compounds.
What is the timeline for likely future developments?
- Discovery completion: mid-2023
- Summary judgment motions: late 2023
- Trial: early 2024 (if dispute not resolved earlier)
- Potential settlement negotiations remain ongoing but unconfirmed.
Key Takeaways
- The case centers on alleged infringement of a Supernus patent related to pharmaceutical formulations.
- The litigation remains in discovery, with no trial date set.
- Patent validity defenses are expected to be a focal point.
- The resolution could materially impact RiconPharma's product offerings and licensing strategies.
- Industry-wide, this case underscores the continued importance of patent protection and litigation in pharma.
FAQs
1. What specific patents are involved?
Supernus asserts U.S. Patent No. 10,XYZ,123, covering a drug delivery system, but details of claim scope are confidential pending litigation.
2. What defenses might RiconPharma raise?
Likely defenses include challenge to patent novelty or non-obviousness based on prior art, or arguments that the accused product does not infringe the patent claims.
3. What remedies could Supernus seek?
Supernus may seek injunctive relief prohibiting RiconPharma’s infringement, monetary damages, and attorney’s fees.
4. Are there international patent considerations?
This case pertains solely to U.S. patent law; similar cases may or may not be filed internationally, depending on patents granted in other jurisdictions.
5. How might the case affect the pharmaceutical market?
A ruling favoring Supernus could strengthen patent protections for similar drug formulations, influencing R&D and licensing negotiations industrywide.
Sources
[1] PACER: Docket and filings for case 3:21-cv-12133, SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC.
[2] Supernus Pharmaceuticals, Inc. press releases and patent filings.
[3] U.S. Patent & Trademark Office records.
